PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer

BJU International

Volumn 85, Issue 4, 2000, Pages 481-485

  Pfeifer, B L ^a   Pirani, J F ^a   Hamann, S R ^b   Klippel, K F ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ALLGEMEINES KRANKENHAUS CELLE   (Germany)

Author keywords

Herbal therapy; Hormone refractory prostate cancer; Pain; PC SPES; PSA

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; HERBACEOUS AGENT; PC SPES; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST DISEASE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG RESISTANCE; DYSPEPSIA; HUMAN; MALE; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0034049685     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00476.x     Document Type: Article

References (11)

1. 1 Landis SH, Murray T, Bolden S et al. Cancer statistics 1998. CA Cancer J Clin 1998; 48: 6-29
2. 2 Klien LA. Prostatic carcinoma. N Engl J Med 1979; 300: 824
3. 3 Parker SL, Tong T, Bolden S et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5
4. 4 Halicka HD, Ardelt B, Juan G et al. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC-SPES. Int J Oncol 1997; 11: 437
5. 5 Hsieh T, Ng C, Chang C et al. Induction of apoptosis and down-regulation of bcl-6 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol 1998; 13: 1199
6. 6 Hsieh T, Chen S, Wang X, Wu J. Regulation of androgen receptor and prostate specific antigen expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int 1997; 42: 535
7. 7 Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using functional assessment of cancer therapy - prostate instrument. Urology 1997; 50: 920
8. 8 Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239
9. 9 Waselenko JK, Dawson NA. Management of progressive metastatic prostate cancer. Oncology 1997; 11: 1551
10. 10 Risberg T, Lund E, Wist E et al. Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 1998; 16: 6
11. 11 DiPaola RS, Zhang H, Lambert GH et al. Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339: 785